Shenyang Xingqi Pharmaceutical Co., Ltd engages in the research and development, production, and sale of ophthalmic products in China. It offers corneal, anti-bacteria, artificial tears, anti-inflammation, surgical perfusate, mydriactics, anti-fatigue, and pre dry and over dry eye treatment products. The company is based in Shenyang, China.

Shenyang Xingqi Pharmaceutical Co.,Ltd

兴齐眼药 is a high-tech enterprise specializing in the research and development, production, and sales of ophthalmic drugs.

Metric
Company Name	Shenyang Xingqi Pharmaceutical Co.,Ltd
Symbol	300.57K
MSH ID	COM:SINQI
Market	STOCKS
Sector	Healthcare
Industry	Medical - Instruments & Supplies
Country	CN
Stage
Employee Count	2.00K
Website	sinqi.com
LinkedIn
Founders

Metric
Market Cap	3.72B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	199.60M
Revenue (LTM)
Revenue (NTM)
Gross Profit	149.42M
EBITDA	48.06M
Operating Income	35.54M
Net Income	33.02M
EPS	0.27
Diluted EPS	0.27
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.77
Operating Profit Margin	0.22
EBITDA Margin	0.24
Net Profit Margin	0.19
Return on Equity	0.20
Return on Assets	0.15
Return on Capital Employed	0.23

3005

COM:SINQI

兴齐眼药

Last Close

80.30

25/11 07:04

Market Cap

27.02B

Beta: -

Volume Today

5.61M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	61.61
P/B Ratio	7.39
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	23.46
EV Multiple	137.35

Metric
Days Sales Outstanding	80.06
Days Payables Outstanding	15.12
Days Inventory Outstanding	148.66
Operating Cycle	224.73
Cash Conversion Cycle	209.61
Asset Turnover	0.80

Metric
Operating Cash Flow	43.68M
Free Cash Flow	7.65M
Cash Flow to Debt	3.17
Operating Cash Flow/Sales	0.24
Free Cash Flow Yield	-0.00

Metric
Cash & Equivalents	66.08M
Accounts Receivable	-14.36M
Inventory	18.71M
Goodwill
Debt to Capitalization	0.16
Debt to Assets	0.03
Current Ratio	3.40
Quick Ratio	2.90

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.13
SG&A to Revenue	0.03